CDC7 and small cell lung carcinoma: We observed that CDC7 knockout induced sensitivity to cisplatin in two cell lines representing distinct SCLC subtypes (H82, SCLC-N and H146, SCLC-A, Supplementary Fig. s5a) and that the combination of simurosertib with either cisplatin or irinotecan, used in the first and second line treatment of SCLC patients, respectively, exerted synergistic effects in vitro in both models (Fig. 6a), associated with induction of apoptosis (Supplementary Fig. s5b).